ACTG Publications

TitleAuthorsDateJournalIssueVolume
Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.Haas, David W ; Bradford, Yuki ; Verma, Anurag ; Verma, Shefali S ; Eron, Joseph J ; Gulick, Roy M ; Riddler, Sharon A ; Sax, Paul E ; Daar, Eric S ; Morse, Gene D ; Acosta, Edward P ; Ritchie, Marylyn D2018 JulPharmacogenet Genomics728
Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.Vardhanabhuti, Saran ; Acosta, Edward P ; Ribaudo, Heather J ; Severe, Patrice ; Lalloo, Umesh ; Kumarasamy, Nagalingeshwaran ; Taulo, Frank ; Kabanda, Joseph ; Oneko, Olola ; Ive, Prudence ; Sambarey, Pradeep ; Chan, Ellen S ; Hitti, Jane ; Hong, Francis ; McMahon, Deborah ; Haas, David W ; A5207 ACTG Study Team2013 Aug 15J Infect Dis4208
Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.Gay, Cynthia L ; Bosch, Ronald J ; Ritz, Justin ; Hataye, Jason M ; Aga, Evgenia ; Tressler, Randall L ; Mason, Stephen W ; Hwang, Carey K ; Grasela, Dennis M ; Ray, Neelanjana ; Cyktor, Josh C ; Coffin, John M ; Acosta, Edward P ; Koup, Richard A ; Mellors, John W ; Eron, Joseph J ; AIDS Clinical Trials 5326 Study Team2017 Jun 01J Infect Dis11215
Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy.Li, Jonathan Z ; Chapman, Brad ; Charlebois, Patrick ; Hofmann, Oliver ; Weiner, Brian ; Porter, Alyssa J ; Samuel, Reshmi ; Vardhanabhuti, Saran ; Zheng, Lu ; Eron, Joseph ; Taiwo, Babafemi ; Zody, Michael C ; Henn, Matthew R ; Kuritzkes, Daniel R ; Hide, Winston ; ACTG A5262 Study Team ; Wilson, Cara C ; Berzins, Baiba I ; Acosta, Edward2014PLoS One39
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.Namazi, Golnaz ; Fajnzylber, Jesse M ; Aga, Evgenia ; Bosch, Ronald J ; Acosta, Edward P ; Sharaf, Radwa ; Hartogensis, Wendy ; Jacobson, Jeffrey M ; Connick, Elizabeth ; Volberding, Paul ; Skiest, Daniel ; Margolis, David ; Sneller, Michael C ; Little, Susan J ; Gianella, Sara ; Smith, Davey M ; Kuritzkes, Daniel R ; Gulick, Roy M ; Mello2018 Nov 05J Infect Dis12218
Design issues in initial HIV-treatment trials: focus on ACTG A5095.Ribaudo, Heather J ; Kuritzkes, Daniel R ; Schackman, Bruce R ; Acosta, Edward P ; Shikuma, Cecilia M ; Gulick, Roy M2006Antivir Ther611
Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.Nyaku, Amesika N ; Zheng, Lu ; Gulick, Roy M ; Olefsky, Maxine ; Berzins, Baiba ; Wallis, Carole L ; Godfrey, Catherine ; Sax, Paul E ; Acosta, Edward P ; Haas, David W ; Smith, Kimberly Y ; Sha, Beverly E ; Van Dam, Cornelius N ; Taiwo, Babafemi O ; ACTG A5353 Study Team2019 Jan 18J Antimicrob Chemother
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.Ribaudo, Heather J ; Kuritzkes, Daniel R ; Lalama, Christina M ; Schouten, Jeffrey T ; Schackman, Bruce R ; Acosta, Edward P ; Gulick, Roy M2008 Apr 1J Infect Dis7197
Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.Acosta, Edward P ; Kendall, Michelle A ; Gerber, John G ; Alston-Smith, Beverly ; Koletar, Susan L ; Zolopa, Andrew R ; Agarwala, Sangeeta ; Child, Michael ; Bertz, Richard ; Hosey, Lara ; Haas, David W2007 SepAntimicrob Agents Chemother951
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.Ribaudo, Heather J ; Liu, Huan ; Schwab, Matthias ; Schaeffeler, Elke ; Eichelbaum, Michel ; Motsinger-Reif, Alison A ; Ritchie, Marylyn D ; Zanger, Ulrich M ; Acosta, Edward P ; Morse, Gene D ; Gulick, Roy M ; Robbins, Gregory K ; Clifford, David ; Haas, David W2010 Sep 1J Infect Dis5202
Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).Taiwo, Babafemi ; Zheng, Lu ; Gallien, Sebastien ; Matining, Roy M ; Kuritzkes, Daniel R ; Wilson, Cara C ; Berzins, Baiba I ; Acosta, Edward P ; Bastow, Barbara ; Kim, Peter S ; Eron, Joseph J ; ACTG A5262 Team2011 Nov 13AIDS1725
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.Gerber, John G ; Kitch, Douglas W ; Fichtenbaum, Carl J ; Zackin, Robert A ; Charles, Stéphannie ; Hogg, Evelyn ; Acosta, Edward P ; Connick, Elizabeth ; Wohl, David ; Kojic, E Milu ; Benson, Constance A ; Aberg, Judith A2008 Apr 1J Acquir Immune Defic Syndr447
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.Holzinger, Emily R ; Grady, Benjamin ; Ritchie, Marylyn D ; Ribaudo, Heather J ; Acosta, Edward P ; Morse, Gene D ; Gulick, Roy M ; Robbins, Gregory K ; Clifford, David B ; Daar, Eric S ; McLaren, Paul ; Haas, David W2012 DecPharmacogenet Genomics1222
Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.Wanga, Valentine ; Venuto, Charles ; Morse, Gene D ; Acosta, Edward P ; Daar, Eric S ; Haas, David W ; Li, Chun ; Shepherd, Bryan E2015 SepPharmacogenet Genomics925
Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir.Haas, David W ; Koletar, Susan L ; Laughlin, Laura ; Kendall, Michelle A ; Suckow, Carol ; Gerber, John G ; Zolopa, Andrew R ; Bertz, Richard ; Child, Michael J ; Hosey, Lara ; Alston-Smith, Beverly ; Acosta, Edward P ; A5213 StudyTeam2009 Mar 1J Acquir Immune Defic Syndr350
HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers.Sharaf, Radwa ; Lee, Guinevere Q ; Sun, Xiaoming ; Etemad, Behzad ; Aboukhater, Layla M ; Hu, Zixin ; Brumme, Zabrina L ; Aga, Evgenia ; Bosch, Ronald J ; Wen, Ying ; Namazi, Golnaz ; Gao, Ce ; Acosta, Edward P ; Gandhi, Rajesh T ; Jacobson, Jeffrey M ; Skiest, Daniel ; Margolis, David M ; Mitsuyasu, Ronald ; Volberding, Paul ; Connick, El2018 Aug 31J Clin Invest9128
Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria.Kshirsagar, Smita A ; Blaschke, Terrence F ; Sheiner, Lewis B ; Krygowski, M ; Acosta, Edward P ; Verotta, Davide2007 FebJ Pharmacokinet Pharmacodyn134
Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.Moore, Jeff D ; Acosta, Edward P ; Johnson, Victoria A ; Bassett, Roland ; Eron, Joseph J ; Fischl, Margaret A ; Long, Mary C ; Kuritzkes, Daniel R ; Sommadossi, Jean-Pierre2007Antivir Ther612
Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s).Clifford, David B ; Evans, Scott ; Yang, Yijun ; Acosta, Edward P ; Ribaudo, Heather ; Gulick, Roy M ; A5097s Study Team2009 Nov-DecHIV Clin Trials610
Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence.Wu, Hulin ; Huang, Yangxin ; Acosta, Edward P ; Park, Jeong-Gun ; Yu, Song ; Rosenkranz, Susan L ; Kuritzkes, Daniel R ; Eron, Joseph J ; Perelson, Alan S ; Gerber, John G2006 AugJ Pharmacokinet Pharmacodyn433
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.Ribaudo, Heather J ; Haas, David W ; Tierney, Camlin ; Kim, Richard B ; Wilkinson, Grant R ; Gulick, Roy M ; Clifford, David B ; Marzolini, Catia ; Fletcher, Courtney V ; Tashima, Karen T ; Kuritzkes, Daniel R ; Acosta, Edward P ; Adult AIDS Clinical Trials Group Study2006 Feb 1Clin Infect Dis342
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.Kuritzkes, Daniel R ; Lalama, Christina M ; Ribaudo, Heather J ; Marcial, Michelle ; Meyer, William A ; Shikuma, Cecilia ; Johnson, Victoria A ; Fiscus, Susan A ; D'Aquila, Richard T ; Schackman, Bruce R ; Acosta, Edward P ; Gulick, Roy M2008 Mar 15J Infect Dis6197
A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115.Riddler, Sharon A ; Jiang, Hongyu ; Tenorio, Allan ; Huang, Hairong ; Kuritzkes, Daniel R ; Acosta, Edward P ; Landay, Alan ; Bastow, Barbara ; Haas, David W ; Tashima, Karen T ; Jain, Mamta K ; Deeks, Steven G ; Bartlett, John A2007Antivir Ther412
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.Haas, David W ; Kwara, Awewura ; Richardson, Danielle M ; Baker, Paxton ; Papageorgiou, Ioannis ; Acosta, Edward P ; Morse, Gene D ; Court, Michael H2014 AugJ Antimicrob Chemother869
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.Andrade, Adriana ; Rosenkranz, Susan L ; Cillo, Anthony R ; Lu, Darlene ; Daar, Eric S ; Jacobson, Jeffrey M ; Lederman, Michael ; Acosta, Edward P ; Campbell, Thomas ; Feinberg, Judith ; Flexner, Charles ; Mellors, John W ; Kuritzkes, Daniel R ; AIDS Clinical Trials Group A5248 Team2013 SepJ Infect Dis6208
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.Gulick, Roy M ; Ribaudo, Heather J ; Shikuma, Cecilia M ; Lalama, Christina ; Schackman, Bruce R ; Meyer, William A ; Acosta, Edward P ; Schouten, Jeffrey ; Squires, Kathleen E ; Pilcher, Christopher D ; Murphy, Robert L ; Koletar, Susan L ; Carlson, Margrit ; Reichman, Richard C ; Bastow, Barbara ; Klingman, Karin L ; Kuritzkes, Daniel R 2006 Aug 16JAMA7296